Skip to main content

Table 4 Incremental cost impact (total and per patient) compared to lowest cost and standard of care

From: Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa

Total Inc. impact (2018)

Total Incrementalcost (USD)

Incremental costper pt (USD) Yr 1

1wk AmBd/5FC

 vs 1wk AmBd/Flu (LC)

9,600,890

1373

 vs 2wk AmBd/Flu (SC)

2,045,359

293